Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, Global First CLDN18.2 ADC Drug Application Accepted for Gastric Cancer

Market Focus

06/05

On June 5, Innovent Biologics rose 3.01% in regular trading, trading at 78.7 HKD/share, with trading volume of 341 million HKD.

On the news front, the company announced on June 4 that the New Drug Application for its CLDN18.2-targeted ADC drug IBI343 (Arcotatug Tavatecan) for advanced gastric cancer was accepted by China's NMPA and granted priority review. IBI343 is the first CLDN18.2-targeted ADC drug globally to enter regulatory review. The drug achieved dual primary endpoints of PFS and OS in an international multi-center Phase III clinical study, demonstrating excellent efficacy and a tolerable safety profile. If approved, it is expected to fill a clinical gap in later-line treatment for advanced gastric cancer.

Additionally, the biotech sector showed broad recovery today, with SKB Bio up 4.97%, Akeso up 2.36%, and Remegen up 2.07%, providing sector-level tailwinds. The stock also benefits from the recent $10.5 billion global strategic partnership with Pfizer announced on May 29, with multiple brokerages maintaining Buy ratings and target prices above 100 HKD.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1128980403"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128980403\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128980403?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128980403","market":"us","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, Global First CLDN18.2 ADC Drug Application Accepted for Gastric Cancer","media":"Market Focus","content":"<p><p>On June 5, Innovent Biologics rose 3.01% in regular trading, trading at 78.7 HKD/share, with trading volume of 341 million HKD.</p><p>On the news front, the company announced on June 4 that the New Drug Application for its CLDN18.2-targeted ADC drug IBI343 (Arcotatug Tavatecan) for advanced gastric cancer was accepted by China's NMPA and granted priority review. IBI343 is the first CLDN18.2-targeted ADC drug globally to enter regulatory review. The drug achieved dual primary endpoints of PFS and OS in an international multi-center Phase III clinical study, demonstrating excellent efficacy and a tolerable safety profile. If approved, it is expected to fill a clinical gap in later-line treatment for advanced gastric cancer.</p><p>Additionally, the biotech sector showed broad recovery today, with SKB Bio up 4.97%, Akeso up 2.36%, and Remegen up 2.07%, providing sector-level tailwinds. The stock also benefits from the recent $10.5 billion global strategic partnership with Pfizer announced on May 29, with multiple brokerages maintaining Buy ratings and target prices above 100 HKD.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, Global First CLDN18.2 ADC Drug Application Accepted for Gastric Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, Global First CLDN18.2 ADC Drug Application Accepted for Gastric Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-06-05 09:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On June 5, Innovent Biologics rose 3.01% in regular trading, trading at 78.7 HKD/share, with trading volume of 341 million HKD.</p><p>On the news front, the company announced on June 4 that the New Drug Application for its CLDN18.2-targeted ADC drug IBI343 (Arcotatug Tavatecan) for advanced gastric cancer was accepted by China's NMPA and granted priority review. IBI343 is the first CLDN18.2-targeted ADC drug globally to enter regulatory review. The drug achieved dual primary endpoints of PFS and OS in an international multi-center Phase III clinical study, demonstrating excellent efficacy and a tolerable safety profile. If approved, it is expected to fill a clinical gap in later-line treatment for advanced gastric cancer.</p><p>Additionally, the biotech sector showed broad recovery today, with SKB Bio up 4.97%, Akeso up 2.36%, and Remegen up 2.07%, providing sector-level tailwinds. The stock also benefits from the recent $10.5 billion global strategic partnership with Pfizer announced on May 29, with multiple brokerages maintaining Buy ratings and target prices above 100 HKD.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信達生物","start_time":0,"source_url":"","article_id":"1128980403","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128980403","pubTimestamp":1780624544,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, Innovent Biologics rose 3.01% in regular trading, trading at 78.7 HKD/share, with trading volume of 341 million HKD.On the news front, the company announced on June 4 that the New Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动静快讯|信达生物常规交易涨3.01%，全球首个CLDN18.2 ADC胃癌药物申请获受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 5, Innovent Biologics rose 3.01% in regular trading, trading at 78.7 HKD/share, with trading volume of 341 million HKD.On the news front, the company announced on June 4 that the New Drug Application for its CLDN18.2-targeted ADC drug IBI343 (Arcotatug Tavatecan) for advanced gastric cancer was accepted by China's NMPA and granted priority review. IBI343 is the first CLDN18.2-targeted ADC drug globally to enter regulatory review. The drug achieved dual primary endpoints of PFS and OS in an international multi-center Phase III clinical study, demonstrating excellent efficacy and a tolerable safety profile. If approved, it is expected to fill a clinical gap in later-line treatment for advanced gastric cancer.Additionally, the biotech sector showed broad recovery today, with SKB Bio up 4.97%, Akeso up 2.36%, and Remegen up 2.07%, providing sector-level tailwinds. The stock also benefits from the recent $10.5 billion global strategic partnership with Pfizer announced on May 29, with multiple brokerages maintaining Buy ratings and target prices above 100 HKD.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}